Your browser doesn't support javascript.
loading
Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.
Quistrebert, Jocelyn; Hässler, Signe; Bachelet, Delphine; Mbogning, Cyprien; Musters, Anne; Tak, Paul Peter; Wijbrandts, Carla Ann; Herenius, Marieke; Bergstra, Sytske Anne; Akdemir, Gülsah; Johannesson, Martina; Combe, Bernard; Fautrel, Bruno; Chollet-Martin, Sylvie; Gleizes, Aude; Donnellan, Naoimh; Deisenhammer, Florian; Davidson, Julie; Hincelin-Mery, Agnès; Dönnes, Pierre; Fogdell-Hahn, Anna; De Vries, Niek; Huizinga, Tom; Abugessaisa, Imad; Saevarsdottir, Saedis; Hacein-Bey-Abina, Salima; Pallardy, Marc; Broët, Philippe; Mariette, Xavier.
Afiliación
  • Quistrebert J; CESP, INSERM UMR 1018, Faculty of Medicine, Paris-Sud University, Paris-Saclay University, UVSQ, Villejuif, France.
  • Hässler S; CESP, INSERM UMR 1018, Faculty of Medicine, Paris-Sud University, Paris-Saclay University, UVSQ, Villejuif, France.
  • Bachelet D; CESP, INSERM UMR 1018, Faculty of Medicine, Paris-Sud University, Paris-Saclay University, UVSQ, Villejuif, France.
  • Mbogning C; CESP, INSERM UMR 1018, Faculty of Medicine, Paris-Sud University, Paris-Saclay University, UVSQ, Villejuif, France.
  • Musters A; Amsterdam Rheumatology and Immunology Center, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
  • Tak PP; Amsterdam Rheumatology and Immunology Center, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands; GlaxoSmithKline, Stevenage, UK; University of Cambridge, Cambridge, UK; Ghent University, Ghent, Belgium.
  • Wijbrandts CA; Amsterdam Rheumatology and Immunology Center, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands; Medical Center Slotervaart, Amsterdam, the Netherlands.
  • Herenius M; Amsterdam Rheumatology and Immunology Center, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
  • Bergstra SA; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Akdemir G; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Johannesson M; Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Combe B; Department of Rheumatology, Lapeyronie Hospital, Montpellier University, Montpellier, France.
  • Fautrel B; Department of Rheumatology, AP-HP, Pitié Salpétrière Hospital, Paris, France; UPMC, GRC 08, Pierre Louis Institute of Epidemiology and Public Health, Paris, France.
  • Chollet-Martin S; INSERM UMR 996, Faculty of Pharmacy, Paris-Sud University, Paris-Saclay University, Châtenay-Malabry, France.
  • Gleizes A; INSERM UMR 996, Faculty of Pharmacy, Paris-Sud University, Paris-Saclay University, Châtenay-Malabry, France; Clinical Immunology Laboratory, AP-HP, Paris-Sud University Hospitals, Le Kremlin Bicêtre Hospital, Le Kremlin Bicêtre, France.
  • Donnellan N; IPSEN, Slough, Berkshire, UK.
  • Deisenhammer F; Department of Neurology, Innsbruck Medical University, Innsbruck, Austria.
  • Davidson J; GlaxoSmithKline, Uxbridge, Middlesex, UK.
  • Hincelin-Mery A; Sanofi, Chilly-Mazarin, France.
  • Dönnes P; SciCross AB, Skövde, Sweden.
  • Fogdell-Hahn A; Department of Clinical Neuroscience, Clinical Neuroimmunology, Karolinska Institutet, Stockholm, Sweden.
  • De Vries N; Amsterdam Rheumatology and Immunology Center, Academic Medical Center of the University of Amsterdam, Amsterdam, the Netherlands.
  • Huizinga T; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Abugessaisa I; Unit of Computational Medicine, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.
  • Saevarsdottir S; Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
  • Hacein-Bey-Abina S; Clinical Immunology Laboratory, AP-HP, Paris-Sud University Hospitals, Le Kremlin Bicêtre Hospital, Le Kremlin Bicêtre, France; UTCBS, CNRS UMR 8258, INSERM U1022, Faculty of Pharmacy, Paris-Descartes-Sorbonne-Cité University, Paris, France.
  • Pallardy M; INSERM UMR 996, Faculty of Pharmacy, Paris-Sud University, Paris-Saclay University, Châtenay-Malabry, France.
  • Broët P; CESP, INSERM UMR 1018, Faculty of Medicine, Paris-Sud University, Paris-Saclay University, UVSQ, Villejuif, France; AP-HP, Paris-Sud University Hospitals, Paul Brousse Hospital, Villejuif, France; CHU Sainte Justine, Quebec, Canada.
  • Mariette X; INSERM U1184, Center for Immunology of Viral Infections and Autoimmune Diseases, Paris-Sud University, Paris-Saclay University, Le Kremlin-Bicêtre, France; Department of Rheumatology, AP-HP, Paris-Sud University Hospitals, Le Kremlin Bicêtre Hospital, Le Kremlin-Bicêtre, France. Electronic address:
Semin Arthritis Rheum ; 48(6): 967-975, 2019 06.
Article en En | MEDLINE | ID: mdl-30420245
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Adalimumab / Infliximab / Anticuerpos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Semin Arthritis Rheum Año: 2019 Tipo del documento: Article País de afiliación: Francia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Artritis Reumatoide / Antirreumáticos / Adalimumab / Infliximab / Anticuerpos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Semin Arthritis Rheum Año: 2019 Tipo del documento: Article País de afiliación: Francia